Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Minor antigen solves major problem

A mouse model for donor lymphocyte infusion reveals that a single immunodominant minor H antigen is responsible for the beneficial effects of donor T lymphocytes against host leukemia. Separating the good from the bad could mean the end of graft-versus-host disease in bone marrow transplants. (pages 789–794)

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The infusion of T cells directed against multiple minor H antigen differences produces severe GvHD (left).

Stephen Horwitz

References

  1. Fontaine, P. et al. Adoptive tranfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nature Med. 7, 789–794 (2001).

    Article  CAS  Google Scholar 

  2. Apperley, J.F. et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant. 1, 53–66 (1986).

    CAS  PubMed  Google Scholar 

  3. Dazzi, F., Szydlo, R.M. & Goldman, J.M. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Exp. Hematol. 27, 1477–1486 (1999).

    Article  CAS  Google Scholar 

  4. Goulmy, E. et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N. Engl. J. Med. 334, 281–285 (1996).

    Article  CAS  Google Scholar 

  5. Barrett, A.J. et al. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant. 21, 543–551 (1998).

    Article  CAS  Google Scholar 

  6. Dazzi, F. et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 95, 67–71 (2000).

    CAS  PubMed  Google Scholar 

  7. Gallucci, S. & Matzinger, P. Danger signals: SOS to the immune system. Curr. Opin. Immunol. 13, 114–119 (2001).

    Article  CAS  Google Scholar 

  8. Krenger, W., Hill, G.R. & Ferrara, J.L. Cytokine cascades in acute graft-versus-host disease. Transplantation 64, 553–558 (1997).

    Article  CAS  Google Scholar 

  9. Mutis, T. et al. Feasibility of immunotherapy of relapsed leukemia with ex vivo- generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 93, 2336–2341 (1999).

    CAS  Google Scholar 

  10. Lehmann, P.V., Forsthuber, T., Miller, A. & Sercarz, E.E. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358, 155–157 (1992).

    Article  CAS  Google Scholar 

  11. Simpson, E. & Roopenian, D. Minor histocompatibility antigens. Curr. Opin. Immunol. 9, 655–661 (1997).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dazzi, F., Simpson, E. & Goldman, J. Minor antigen solves major problem. Nat Med 7, 769–770 (2001). https://doi.org/10.1038/89874

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/89874

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing